Prolonged Shedding of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at High Viral Loads Among Hospitalized Immunocompromised Persons Living With Human Immunodeficiency Virus (HIV), South Africa

Abstract Background We assessed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA shedding duration and magnitude among persons living with human immunodeficiency virus (HIV, PLHIV). Methods From May through December 2020, we conducted a prospective cohort study at 20 hospitals in South Africa. Adults hospitalized with symptomatic coronavirus disease 2019 (COVID-19) were enrolled and followed every 2 days with nasopharyngeal/oropharyngeal (NP/OP) swabs until documentation of cessation of SARS-CoV-2 shedding (2 consecutive negative NP/OP swabs). Real-time reverse transcription-polymerase chain reaction testing for SARS-CoV-2 was performed, and cycle-threshold (Ct) values < 30 were considered a proxy for high SARS-CoV-2 viral load. Factors associated with prolonged shedding were assessed using accelerated time-failure Weibull regression models. Results Of 2175 COVID-19 patients screened, 300 were enrolled, and 257 individuals (155 HIV-uninfected and 102 PLHIV) had > 1 swabbing visit (median 5 visits [range 2–21]). Median time to cessation of shedding was 13 days (interquartile range [IQR] 6–25) and did not differ significantly by HIV infection. Among a subset of 94 patients (41 PLHIV and 53 HIV-uninfected) with initial respiratory sample Ct-value < 30, median time of shedding at high SARS-CoV-2 viral load was 8 days (IQR 4–17). This was significantly longer in PLHIV with CD4 count < 200 cells/µL, compared to HIV-uninfected persons (median 27 days [IQR 8–43] vs 7 days [IQR 4–13]; adjusted hazard ratio [aHR] 0.14, 95% confidence interval [CI] .07–.28, P < .001), as well as in unsuppressed-HIV versus HIV-uninfected persons. Conclusions Although SARS-CoV-2 shedding duration did not differ significantly by HIV infection, among a subset with high initial SARS-CoV-2 viral loads, immunocompromised PLHIV shed SARS-CoV-2 at high viral loads for longer than HIV-uninfected persons. Better HIV control may potentially decrease transmission time of SARS-CoV-2.

[1]  Christine S. Smedley,et al.  Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study , 2021, The Lancet HIV.

[2]  D. Ip,et al.  Is oropharyngeal sampling a reliable test to detect SARS-CoV-2? – Authors' reply , 2021, The Lancet Infectious Diseases.

[3]  A. Sigal,et al.  Persistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infection , 2021, medRxiv.

[4]  F. Ginhoux,et al.  Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis , 2021, Cell Death & Differentiation.

[5]  B. Cowling,et al.  Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis , 2021, The Lancet Infectious Diseases.

[6]  Y. Yazdanpanah,et al.  Long term SARS-CoV-2 infectiousness among three immunocompromised patients: from prolonged viral shedding to SARS-CoV-2 superinfection , 2021, The Journal of infectious diseases.

[7]  A. Sigal,et al.  Sixteen novel lineages of SARS-CoV-2 in South Africa , 2021, Nature Medicine.

[8]  L. Morris,et al.  SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma , 2021, bioRxiv.

[9]  M. M. van der Eerden,et al.  Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19) , 2021, Nature communications.

[10]  N. E. Babady,et al.  Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer , 2020, The New England journal of medicine.

[11]  Gaurav D. Gaiha,et al.  Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host , 2020, The New England journal of medicine.

[12]  A. Charlett,et al.  Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[13]  Ilya J. Finkelstein,et al.  Structure-based design of prefusion-stabilized SARS-CoV-2 spikes , 2020, Science.

[14]  M. Nannipieri,et al.  Obesity prolongs the hospital stay in patients affected by COVID-19, and may impact on SARS-COV-2 shedding , 2020, Obesity Research & Clinical Practice.

[15]  P. V. Van Caeseele,et al.  Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples , 2020, Clinical Infectious Diseases.

[16]  M. Mina,et al.  To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  Z. Tong,et al.  Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020 , 2020, Emerging infectious diseases.

[18]  George M. Varghese,et al.  Clinical management of COVID-19 , 2020, The Indian journal of medical research.

[19]  T. Liang,et al.  Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study , 2020, BMJ.

[20]  Jun Liu,et al.  Factors associated with prolonged viral RNA shedding in patients with COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  P. Vollmar,et al.  Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.

[22]  O. Tsang,et al.  Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study , 2020, The Lancet Infectious Diseases.

[23]  Eric H. Y. Lau,et al.  Temporal dynamics in viral shedding and transmissibility of COVID-19 , 2020, Nature Medicine.

[24]  W. Cao,et al.  Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia , 2020, Emerging microbes & infections.

[25]  Paul A. Harris,et al.  The REDCap consortium: Building an international community of software platform partners , 2019, J. Biomed. Informatics.

[26]  E. Variava,et al.  Influenza Viral Shedding in a Prospective Cohort of HIV-Infected and Uninfected Children and Adults in 2 Provinces of South Africa, 2012–2014 , 2018, The Journal of infectious diseases.

[27]  E. Harris,et al.  Obesity Increases the Duration of Influenza A Virus Shedding in Adults , 2018, The Journal of infectious diseases.

[28]  Adil Rafiq Rather,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) , 2015 .

[29]  Marc Lipsitch,et al.  Estimating Variability in the Transmission of Severe Acute Respiratory Syndrome to Household Contacts in Hong Kong, China , 2007, American journal of epidemiology.

[30]  D. Collet.  Modelling Survival Data in Medical Research , 2004 .

[31]  J. Peiris,et al.  Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study , 2003, The Lancet.

[32]  L. Gubareva,et al.  Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. , 2003, The New England journal of medicine.

[33]  An Overview of Cycle Threshold Values and their Role in SARS-CoV-2 Real-Time PCR Test Interpretation , 2020 .

[34]  P. Cadrobbi,et al.  Antigenic Drift of Influenza a (h3n2) Virus in a Persistently Infected Immunocompromised Host Is Similar to That Occurring in the Community , 2022 .